BIO 2026: Vir is scheduled to have its first phase 3 readout in Hepatitis Delta before the end of the year - they believe that their dual mechanism is the difference maker here

1 day ago
1 min read

President & CEO Marianne De Backer describes the unmet need in Hepatitis Delta and why she believes the dual antibody + siRNA is the right approach in this case. Plus, how investors thing about infectious disease vs oncology.

https://vimeo.com/1204340776

Coverage brought to you by

Recent Posts

See All

Artiva's cell therapy approach to autoimmune conditions is unique because it is NK cell based, donor derived, and there is no engineering of the cells - they believe the benefit is already in the data

BIO 2026: AltruBio believes that its PSGL-1, a T-cell checkpoint targeting antibody, could be a "ceiling raiser" in the I&I space

BIO 2026: Kivu Bioscience exited stealth late last year to develop "kinder and gentler" antibody-drug conjugates with a lower antibody to payload ratio to improve precision and tolerability

BIO 2026: Vir is scheduled to have its first phase 3 readout in Hepatitis Delta before the end of the year - they believe that their dual mechanism is the difference maker here

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight